Survodutide (also known as BI 456906) is a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, jointly developed by Boehringer Ingelheim and Zealand Pharma, and is intended to treat metabolic diseases such as obesity and non-alcoholic steatohepatitis.
Survodutide is a drug with an innovative mechanism of action and is expected to become a potential option for the treatment of obesity and metabolic-related diseases. Multiple clinical studies are underway to evaluate its safety and efficacy.
Basic Info. Drostanolone enanthate is an analytical reference standard categorized as an anabolic androgenic steroid prodrug of drostanolone. ...
Basic Info. STANOZOLOL suspension primarily serves a therapeutic role in managing hereditary angioedema caused by C1-inhibitor deficiency. It helps regulate the body's complement system, reducing the frequency and severity of angioedema attacks that affect areas like the skin, airway, or gastrointestinal tract. ...
Basic Info. STANOZOLOL suspension primarily serves a therapeutic role in managing hereditary angioedema caused by C1-inhibitor deficiency. It helps regulate the body's complement system, reducing the frequency and severity of angioedema attacks that affect areas like the skin, airway, or gastrointestinal tract. ...
Basic Info. Boldenone undecylenate, is an androgen and anabolic steroid (AAS) medication which is used in veterinary medicine, mainly in horses. It was formerly used in humans as well. It is given by injection into muscle. ...
Basic Info. Boldenone undecylenate, is an androgen and anabolic steroid (AAS) medication which is used in veterinary medicine, mainly in horses. It was formerly used in humans as well. It is given by injection into muscle. ...
